Address
1 Corporate Drive
South San Francisco, CA 94080

Contact
contact@soley.ai

Our science page sunbeam background

Cells Are Our Guiding Light

Our proprietary approach uses cellular stress signals to enable an unprecedented ability to discover novel therapeutics.

Why can cancer cells thrive under harsh conditions, while brain and heart muscle cells begin to die within minutes of exposure to low oxygen and nutrients? These cells exhibit similar responses to the same stimuli, yet they meet completely different fates.

Group 392@2x

Cancer Cells Become stronger, more aggressive, therapy-resistant, and potentially metastatic.

Group 393@2x

Cardiomyocytes, among other cells, become dysfunctional, and require revascularization to avoid death.

Decoding Cellular Language

Cells are the most powerful computers ever created. Over billions of years of evolution, cells from vastly different organisms have learned to adapt and respond to their environment in a remarkably similar fashion. 

By pinpointing and interpreting these commonalities, we begin to decode the language of cells. Through our founding research, we have defined and validated a common Cellular Language across an array of diseases. As we become more fluent in this Cellular Language, we are able to prognosticate cell fate with unprecedented proficiency.

Catalyzing Discovery With the Power of AI/ML

We harness the computing power of cells as sensors, and augment human intelligence with AI/ML to effectively and efficiently discover and develop drugs.

Our Platform

Dan Von Hoff, M.D.

  • 30+ years pioneer in oncology drug development
  • Distinguished Professor and Physician in Chief, Translational Genomics Research Institute
  • Professor of Medicine at University of Arizona and Mayo Clinic
  • Former National Cancer Advisory Board Member
  • Past President of the American Association for Cancer Research
  • Contributed to development of Abraxane®(nab-paclitaxel), Camptosar® irinotecan, Gemzar® gemcitabine and many other

Afsaneh Naimollah

Linkedin
  • 30+ years of experience corporate finance, strategy advisory and investment banking
  • Executive in Residence, Plug and Play Tech Center
  • Managing Partner, XEN Partners
  • Former Global Head of Barclays Capital Technology Group

Leo Grady, PhD

Linkedin
  • 20+ years of industry experience leading AI/ML, computer vision, and digital health tech
  • Founder and CEO, Stealth AI healthcare company
  • Former CEO of PaigeAI
  • Former SVP of Engineering, Heartflow
  • Founder and CEO of Jona
  • CEO in Residence at Breyer Capital

Fei-Fei Li, PhD

Linkedin
  • Sequoia Professor of Computer Science, Stanford University
  • Co-Director, Stanford Human Centered AI Institute
  • Creator of ImageNet
  • Co-Founder, Chairperson of the Board, AI4ALL
  • Former Chief Scientist of AI/ML, VP Google

Peter Libby, MD

Linkedin
  • Mallinckrodt Professor of Medicine, Cardiovascular Specialist, Harvard Medical School and Brigham and Women’s Hospital
  • World renowned expert in atherosclerosis, cardiovascular medicine and clonal hematopoiesis of indeterminate potential

Keith Flaherty, MD

  • Professor of Medicine, Harvard Medical School
  • Director of Clinical Research, Cancer Center, Massachusetts General Hospital
  • 25+ years expertise in oncology research, drug development, and targeted cancer therapies
  • Co-founder of Loxo Oncology, X4-Pharma, Strata Oncology, Apricity Oncology, Scorpion Therapeutics

Clay Johnston, MD, PhD

Linkedin
  • Professor of Neurology
  • Inaugural Dean, Dell Medical School, UT Austin
  • Former Associate Vice Chancellor of Research, UCSF
  • Co-Founder, Harbor Health

Tony Adamis, MD

  • 30+ years of industry R&D experience
  • Former SVP, Development Innovation, Genentech
  • Co-discovery of VEGF in ocular disease
  • Co-founder, Director, EyeBio

Antoine Yver, MD

Linkedin
  • 30+ years experience and world leader in oncology drug development
  • Board Member, Sanofi
  • Former Head of Oncology Global Medicine Development, AstraZeneca
  • Former Chairman of Development, Centessa
  • Former EVP, Global Head of Oncology R&D, Daiichi Sankyo
  • Contributed to development of Tagrisso® osimertinib, Lynparza® olaparib, Enhertu® trastuzumab deruxtecan and many other

Dan Von Hoff, MD

Co-Founder, CEO, Board Member

Linkedin
  • 30 years of academic experience in patient care, teaching, clinical/basic and stem cell research
  • Expertise in physiologic cellular stress, stem cells, cardiomyocytes, and neuronal cells
  • The Johns Hopkins School of Medicine (1995): M.D.
  • Harvard Medical School / Brigham and Women’s Hospital (1995-2003): internship, residency, chief residency, general and interventional cardiology
  • UCSF (since 2003): Translational Cardiac Stem Cell Program: Founder and Director